US Stocks Movement: Nanobiotix surged on October 27 due to clinical data on melanoma and NBTXR3

Interpretation of Nanobiotix's Surge on October 27

Keywords: Melanoma clinical data, NBTXR3

On October 24, 2026, Nanobiotix announced the final data from a phase I study of JNJ-1900 NBTXR3 combined with immune checkpoint inhibitors for the treatment of anti-PD-1 resistant primary cutaneous melanoma: objective response rate in 24 patients was 41.7% (10 out of 24), including 4 complete remissions; disease control rate was 75% (18 out of 24), and median overall survival was 17.8 months.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)